Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors


share with twitter share with LinkedIn share with facebook
share via e-mail
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.


PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.


Jane Baj

PTC Therapeutics, Inc.


[email protected]

Sheryl Seapy

Pure Communications

[email protected]

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
07:51a SIAULIU BANKAS : Notification on the transaction concluded by manager in issuer's securities
07:50a SOGEFI : filter technologies are present on top engine at International Engine of the Year Award 2017
07:50a WABERER INTERNATIONAL : Romanian Tax Authority decision
07:48a TELENOR : Presentation of Telenor's third quarter 2017 results on 25 October 2017
07:45a CREDIT SUISSE : Activist Investor RBR Capital Advisors confirms talks with Credit Suisse
07:45a DAIMLER - FLEETBOARD NXTLOAD : Saloodo! now on board
07:45a KAMAZ : Guest lecture in engineering center
07:45a YAMAHA MOTOR : Launches Slim & Elegant MIO S Scooter in Indonesia, Increasing Sales in Highest-Demand Category with Design User Friendly for Petite Women
07:45a REMY COINTREAU : Press release – First half sales 2017/18
07:43a BOMBARDIER : Completes Delivery of 14 New INNOVIA Metro Trains for Kuala Lumpur
Latest news "Companies"